OptimizeRx - OPRX Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPRX shares.
View OPRX analyst ratings or view top-rated stocks.

7 brokerages have issued 1-year price objectives for OptimizeRx's stock. Their OPRX share price forecasts range from $16.00 to $66.00. On average, they anticipate the company's share price to reach $27.43 in the next year. This suggests a possible upside of 95.1% from the stock's current price.
View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts.

OptimizeRx's stock was trading at $16.80 at the beginning of 2023. Since then, OPRX stock has decreased by 16.3% and is now trading at $14.06.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our OPRX earnings forecast.

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by $0.04. The business earned $16.13 million during the quarter, compared to the consensus estimate of $14.82 million. OptimizeRx had a negative trailing twelve-month return on equity of 7.12% and a negative net margin of 18.30%. During the same quarter in the previous year, the company earned ($0.01) earnings per share.

ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD), Fidelity Digital Health ETF (FDHT), Global X Telemedicine & Digital Health ETF (EDOC), Invesco S&P SmallCap Health Care ETF (PSCH).

OptimizeRx updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.50 million-$13.00 million, compared to the consensus revenue estimate of $16.15 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

OptimizeRx's stock is owned by many different institutional and retail investors. Top institutional investors include Blair William & Co. IL (4.76%), First Light Asset Management LLC (2.11%), Credit Suisse AG (1.94%), Geode Capital Management LLC (1.84%), Kornitzer Capital Management Inc. KS (1.75%) and Rice Hall James & Associates LLC (1.58%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, Gregory D Wasson, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends.

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPRX stock can currently be purchased for approximately $14.06.

OptimizeRx (NASDAQ:OPRX) has a market capitalization of $240.43 million and generates $62.45 million in revenue each year. The company earns $-11,440,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529.